Ph 3 STELLAR clinical study results showing clinically meaningful benefits with eflornithine + lomustine in patients with grade 3 astrocytoma
“For 30 years, SNO has been at the forefront of neuro-oncology, driving discovery and improving patient care, which is why we are excited to have these encouraging results from the STELLAR Study presented at this meeting,” said Jason Levin, President and Chief Executive Officer at Orbus. “In patients with recurrent WHO 2021 grade 3 IDH-mutant astrocytoma, eflornithine not only improved overall survival but, as determined by a blinded independent central review, improved progression-free survival as well. I believe these data, while taken from a subset analysis, represent one of the first meaningful advances for a patient population in which outcomes have been poor for years.”
Share:
More News
“Initiation of the TEADCO Phase 1b/2 basket trial is another important milestone for the ODM-212 clinical development program and reflects our commitment to patients with difficult-to-treat cancers,” said Professor Outi Vaarala, Executive Vice President, Research & Development at Orion. “Together with the ongoing TEADES study, TEADCO highlights the versatility of
“In this study, tovecimig showed an impressive overall response rate which translated into a clinically meaningful and highly statistically significant improvement in PFS for patients with previously treated BTC. The remarkable 56% reduction in the risk of disease progression is unprecedented in this patient population without an actionable mutation in
“We are encouraged to see taletrectinib (IBTROZI) added to the NCCN Guidelines® for CNS Cancers given its demonstrated high rates of intracranial response that are durable in ROS1+ NSCLC patients with brain metastases,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “Given the prevalence of
Daniel Getts, Ph.D., CEO of CREATE, added “MT-304 is proof of what our platform can do, and what our team can execute. Our mRNA-LNP leadership enables us to move from concept to clinic with remarkable speed. Just last weekend at AACR, we presented compelling preclinical data across our in vivo